SOL Capital Management CO Buys 5,817 Shares of Humana Inc. (NYSE:HUM)

SOL Capital Management CO lifted its stake in shares of Humana Inc. (NYSE:HUM) by 89.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 12,300 shares of the insurance provider’s stock after buying an additional 5,817 shares during the quarter. SOL Capital Management CO’s holdings in Humana were worth $3,121,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Creative Financial Designs Inc. ADV raised its stake in Humana by 244.0% in the 3rd quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock worth $27,000 after purchasing an additional 61 shares in the last quarter. Atwood & Palmer Inc. acquired a new position in Humana during the third quarter worth about $29,000. Ashton Thomas Securities LLC bought a new position in shares of Humana in the third quarter worth about $31,000. Your Advocates Ltd. LLP boosted its stake in shares of Humana by 81.8% in the 3rd quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock valued at $32,000 after purchasing an additional 45 shares in the last quarter. Finally, LRI Investments LLC grew its holdings in shares of Humana by 1,021.4% during the 3rd quarter. LRI Investments LLC now owns 157 shares of the insurance provider’s stock valued at $50,000 after purchasing an additional 143 shares during the last quarter. Institutional investors own 92.38% of the company’s stock.

Humana Stock Performance

Humana stock opened at $296.88 on Friday. The firm has a fifty day simple moving average of $275.44 and a two-hundred day simple moving average of $303.07. Humana Inc. has a twelve month low of $213.31 and a twelve month high of $406.46. The company has a market capitalization of $35.75 billion, a PE ratio of 26.30, a P/E/G ratio of 2.22 and a beta of 0.55. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 EPS for the quarter, topping the consensus estimate of $3.48 by $0.68. The company had revenue of $29.30 billion for the quarter, compared to the consensus estimate of $28.66 billion. Humana had a net margin of 1.18% and a return on equity of 13.20%. Research analysts expect that Humana Inc. will post 16.11 EPS for the current year.

Insider Activity

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the company’s stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the transaction, the insider now owns 8,181 shares of the company’s stock, valued at $2,096,463.06. This represents a 31.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 0.32% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Bank of America upgraded Humana from an “underperform” rating to a “neutral” rating and increased their price target for the company from $247.00 to $308.00 in a research note on Wednesday, November 6th. Stephens restated an “equal weight” rating and issued a $250.00 target price on shares of Humana in a report on Wednesday, October 9th. Wells Fargo & Company lowered their price objective on shares of Humana from $387.00 to $290.00 and set an “overweight” rating for the company in a research note on Monday, November 4th. TD Cowen raised their target price on Humana from $261.00 to $268.00 and gave the company a “hold” rating in a research note on Monday, November 4th. Finally, Morgan Stanley increased their price target on Humana from $288.00 to $301.00 and gave the stock an “equal weight” rating in a report on Tuesday, December 17th. Nineteen equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, Humana has an average rating of “Hold” and a consensus target price of $297.68.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.